Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Retinal Vein Occlusion Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Retinal Vein Occlusion Overview | 8 | 1 |
| Retinal Vein Occlusion Therapeutics under Development by Companies | 9 | 1 |
| Retinal Vein Occlusion Pipeline Products Glance | 10 | 3 |
| Late Stage Products | 10 | 1 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Retinal Vein Occlusion Products under Development by Companies | 13 | 1 |
| Retinal Vein Occlusion Companies Involved in Therapeutics Development | 14 | 9 |
| Aerpio Therapeutics, Inc. | 14 | 1 |
| Clearside BioMedical, Inc. | 15 | 1 |
| Formycon AG | 16 | 1 |
| Kala Pharmaceuticals, Inc. | 17 | 1 |
| Mabion SA | 18 | 1 |
| NicOx S.A. | 19 | 1 |
| Ohr Pharmaceutical Inc. | 20 | 1 |
| Precision Ocular Ltd | 21 | 1 |
| ThromboGenics NV | 22 | 1 |
| Retinal Vein Occlusion Therapeutics Assessment | 23 | 10 |
| Assessment by Monotherapy Products | 23 | 1 |
| Assessment by Combination Products | 24 | 1 |
| Assessment by Target | 25 | 2 |
| Assessment by Mechanism of Action | 27 | 2 |
| Assessment by Route of Administration | 29 | 2 |
| Assessment by Molecule Type | 31 | 2 |
| Drug Profiles | 33 | 33 |
| (aflibercept + triamcinolone acetonide) Drug Profile | 33 | 3 |
| aflibercept biosimilar Drug Profile | 36 | 1 |
| AKB-9778 Drug Profile | 37 | 4 |
| HO-10 Drug Profile | 41 | 1 |
| LKA-651 Drug Profile | 42 | 1 |
| loteprednol etabonate Drug Profile | 43 | 3 |
| NCX-422 Drug Profile | 46 | 1 |
| NCX-434 Drug Profile | 47 | 1 |
| ocriplasmin Drug Profile | 48 | 6 |
| ranibizumab biosimilar Drug Profile | 54 | 1 |
| ranibizumab biosimilar Drug Profile | 55 | 2 |
| Small Molecule for Ophthalmology and Orphan Diseases Drug Profile | 57 | 1 |
| squalamine lactate Drug Profile | 58 | 8 |
| Retinal Vein Occlusion Dormant Projects | 66 | 1 |
| Retinal Vein Occlusion Discontinued Products | 67 | 1 |
| Retinal Vein Occlusion Product Development Milestones | 68 | 7 |
| Featured News &Press Releases | 68 | 1 |
| Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting | 68 | 1 |
| Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion | 68 | 1 |
| Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion | 69 | 1 |
| Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration | 70 | 1 |
| Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion | 70 | 1 |
| Apr 23, 2015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion | 71 | 1 |
| Aug 11, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion | 72 | 1 |
| Jul 31, 2014: Kala Pharmaceuticals Initiates Phase 2 Clinical Trial to Evaluate LE-MPP (KPI-121) in Patients with Retinal Vein Occlusion and Diabetic Macular Edema | 73 | 1 |
| Aug 20, 2013: Ohr Pharmaceutical Announces Investigator Sponsored Trial of Squalamine Eye Drops in Retinal Vein Occlusion | 74 | 1 |
| Appendix | 75 | 2 |
| Methodology | 75 | 1 |
| Coverage | 75 | 1 |
| Secondary Research | 75 | 1 |
| Primary Research | 75 | 1 |
| Expert Panel Validation | 75 | 1 |
| Contact Us | 75 | 1 |
| Disclaimer | 76 | 1 |